Covidien Plc. (COV) 103.35 $COV
Announcement under Irish Takeover Rules Relevant Securities in Issue - December 23, 2014
Business Wire - Tue Dec 23, 7:03AM CST
In accordance with Rule 2.10 of the Irish Takeover Rules, Covidien plc (NYSE: COV) (the "Company"
confirms that, as of the close of business on December 22, 2014, the Company's issued share capital, excluding treasury shares, consisted of 453,883,765 ordinary shares, par value US$0.20 per share (the "Ordinary Shares" . The International Securities Identification Number (ISIN) of the Ordinary Shares is IE00B68SQD29.
COV: 103.35 (+0.57)
Watch for Covidien to Potentially Pullback After Gaining 1.13% Yesterday
Comtex SmarTrend(R) - Mon Dec 22, 4:00PM CST
Covidien (NYSE:COV) traded in a range yesterday that spanned from a low of $102.83 to a high of $104.06. Yesterday, the shares gained 1.1%, which took the trading range above the 3-day high of $103.89 on volume of 3.9 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
COV: 103.35 (+0.57)
After Yesterday's Rally of 1.13% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Mon Dec 22, 3:59PM CST
Covidien (NYSE:COV) traded in a range yesterday that spanned from a low of $102.83 to a high of $104.06. Yesterday, the shares gained 1.1%, which took the trading range above the 3-day high of $103.89 on volume of 3.9 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
COV: 103.35 (+0.57)
Covidien's board declares USD0.36 per ordinary share dividend
M2 - Mon Dec 22, 7:13AM CST
Covidien (NYSE:COV), a health care company, declared on Friday that its board of directors approved a dividend of USD0.36 per ordinary share of its stock.
COV: 103.35 (+0.57)
5 Health Care Stocks John Paulson Is Buying Ahead of 2015
at The Street - Mon Dec 22, 6:00AM CST
Here's a closer look at five stocks Paulson & Co. bought in the most recently reported quarter.
MNK: 97.84 (-0.29), HCA: 74.89 (-0.11), COV: 103.35 (+0.57), MYL: 56.97 (+0.39), ABBV: 66.21 (+1.86)
Covidien declares $0.36 dividend
Seeking Alpha - at Seeking Alpha - Fri Dec 19, 3:39PM CST
COV: 103.35 (+0.57)
Covidien Declares Quarterly Cash Dividend
Business Wire - Fri Dec 19, 3:30PM CST
Covidien plc (NYSE: COV) today announced that its Board of Directors has declared a quarterly cash dividend of $0.36 per ordinary share. The quarterly dividend is payable on Jan. 16, 2015, to shareholders of record on Jan. 2, 2015.
COV: 103.35 (+0.57)
Great Stocks: Mallinckrodt Rebounds, But Is It A Buy?
at Investor's Business Daily - Thu Dec 18, 5:09PM CST
Specialty drugmaker Mallinckrodt (MNK) has rebounded off its 10-week moving average for the third time since it broke out of a cup base in early September. But should investors buy the bounce? Mallinckrodt cleared an 83.30 cup-base buy point Sept. 3...
MNK: 97.84 (-0.29), COV: 103.35 (+0.57)
41.5% Return Seen to Date on SmarTrend Covidien Call (COV)
Comtex SmarTrend(R) - Thu Dec 18, 9:42AM CST
SmarTrend identified an Uptrend for Covidien (NYSE:COV) on May 12th, 2014 at $72.16. In approximately 7 months, Covidien has returned 41.55% as of today's recent price of $102.14.
COV: 103.35 (+0.57)
Masimo's Multigas Monitoring Module Gets 510(k), CE Mark - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Dec 17, 4:55PM CST
Masimo Corporation's (MASI) ISA OR+ multigas monitoring is a Masimo Open Connect (MOC-9) Module for the Root patient monitoring and connectivity platform.
MASI: 26.60 (+0.04), GMED: 24.37 (+0.44), COV: 103.35 (+0.57), EW: 130.75 (+1.17)
New Study Shows Addition of Stent Thrombectomy More Effective Than Traditional Pharmaceutical Treatment for Acute Ischemic Stroke Patients
Business Wire - Wed Dec 17, 9:01AM CST
In a landmark study evaluating the addition of stent thrombectomy clot removal to pharmaceutical treatment for patients suffering an acute ischemic stroke (AIS), stent thrombectomy provided a significant clinical benefit when compared to pharmaceutical treatment alone. Results from the Multi center Randomized Clinical trial of Endovascular treatment for Acute ischemic stroke in the Netherlands (MR CLEAN) have been published online and will appear in the January 1 issue of The New England Journal of Medicine ("NEJM" . Findings were also presented at the World Stroke Congress, confirming the effectiveness of stent thrombectomy.
COV: 103.35 (+0.57)
Covidien's Unique Capsule Endoscopy PillCam(R) SB Featured in New Smithsonian Exhibit 'Tools: Extending Our Reach'
Business Wire - Wed Dec 17, 6:57AM CST
PillCam(R) SB, Covidien's wireless capsule endoscope, is now featured in the exhibit, "Tools: Extending Our Reach" at New York's Cooper Hewitt Smithsonian Design Museum. PillCam SB is one of 175 installations highlighting how tools and innovations have extended the capabilities of the human body over the past two million years. The museum reopened on Dec. 12 after a three year renovation.
COV: 103.35 (+0.57)
Ostomy and Incontinence Products - 2014 Global Strategic Business Report: Incontinence Products Market to Thrive on Ageing Demographics
M2 - Wed Dec 17, 3:34AM CST
Research and Markets (http://www.researchandmarkets.com/research/v9dgkd/ostomy_and) has announced the addition of the "Ostomy and Incontinence Products - Global Strategic Business Report" report to their offering. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2013 through 2020. Also, a seven-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. This report analyzes the worldwide markets for Ostomy and Incontinence Products in US$ Thousands by the following Product Segments: - Incontinence Products (Disposable Adult Diapers, Disposable Adult Shields, Disposable Under Pads, Bags, Clamps, Cleaners, Deodorizers, & Urinals) - Ostomy Products (Ostomy Bags/Pouches, Deodorants, Irrigation Products, & Skin Barriers/Care Products). The report profiles 83 companies including many key and niche players such as: - Attends Healthcare Products, Inc. - B. Braun Melsungen AG - Cloplast A/S - ConvaTec, Inc. - Covidien Ltd. Key Topics Covered: I. Introduction, Methodology & Product Definitions II. Executive Summary 1. Global Market Overview 2. Key Growth Drivers & Restraints 3. Competition 4. Market Trends & Issues 5. Ostomy & Incontinence At A Glance 6. Treatment Options For Incontinence 7. Ostomy And Incontinence Products An Overview 8. Product Developments/Introductions 9. Recent Industry Activity 10. Focus On Select Global Players 11. Global Market Perspective III. Market 1. The United States 2. Canada 3. Japan 4. Europe 5. Asia-Pacific 6. Latin America 7. Rest Of World IV. Competitive Landscape Total Companies Profiled: 83 (including Divisions/Subsidiaries 97) - The United States (62) - Canada (2) - Japan (5) - Europe (22) - France (1) - Germany (3) - The United Kingdom (7) - Italy (1) - Rest of Europe (10) - Asia-Pacific (Excluding Japan) (6) For more information visit http://www.researchandmarkets.com/research/v9dgkd/ostomy_and
COV: 103.35 (+0.57)
Tax Inversions In The U.S.: We Gotta Get Out Of This Place
Cornell Business Review - Seeking Alpha - Sun Dec 14, 1:12PM CST
By Hunter Bosson Following a summer filled with foreign mergers, tax inversions have become the innovative and morally dubious business practice of 2014. As American firms shift their headquarters overseas, widespread claims that a continued...
MDT: 74.08 (+0.31), COV: 103.35 (+0.57), SHPG: 209.29 (+0.07), ABBV: 66.21 (+1.86), BKW: 35.50 (-1.16)
What Investors Can Learn From The Portfolios Of Fund Managers
Elite Wealth Management - at Seeking Alpha - Sun Dec 14, 4:47AM CST
MU: 34.91 (-0.06), ACT: 254.20 (-1.68), C: 54.54 (+0.12), COV: 103.35 (+0.57), CVI: 39.62 (unch), AET: 89.59 (+0.14), PCLN: 1,149.78 (+2.17), FDML: 15.99 (-0.40), TWX: 85.58 (-0.20), STAY: 19.60 (-0.31), HCA: 74.89 (-0.11), EBAY: 57.10 (-0.12), MRVL: 14.33 (+0.01), SUNE: 19.50 (+0.01), SHPG: 209.29 (+0.07), GLD: 112.77 (+0.03), GM: 33.43 (-0.13), IEP: 94.25 (+0.56), GOOGL: 536.93 (-1.84), TWC: 151.15 (+0.17), AIG: 56.28 (-0.16), AAPL: 112.01 (-0.53)
After Yesterday's Decline of 1.73%, Covidien Offers Investors Better Value
Comtex SmarTrend(R) - Wed Dec 10, 4:09PM CST
Covidien (NYSE:COV) traded in a range yesterday that spanned from a low of $101.49 to a high of $103.33. Yesterday, the shares fell 1.7%, which took the trading range below the 3-day low of $102.00 on volume of 3.0 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
COV: 103.35 (+0.57)
Health Care Stocks: A Year in Review and Predictions for 2015
at The Street - Wed Dec 10, 10:38AM CST
In 2014 drugmakers long on cash but short on growth bought quick access to markets that would have otherwise taken years to build. Can this continue?
ZMH: 114.11 (+0.64), ENDP: 72.10 (+0.34), BDX: 139.90 (+1.44), MDT: 74.08 (+0.31), COV: 103.35 (+0.57), ITMN: 73.89 (-0.02), BMY: 59.15 (-0.01), GSK: 42.85 (+0.11), JNJ: 104.59 (+0.31), CBST: 100.29 (-0.09), CFN: 59.18 (+0.04), SHPG: 209.29 (+0.07), AUXL: 34.40 (+0.18), ABBV: 66.21 (+1.86), IDIX: 24.50 (+0.05), SYK: 96.00 (-0.61), NVS: 93.91 (+0.66)
Announcement under Irish Takeover Rules Relevant Securities in Issue - December 23, 2014
Business Wire - Tue Dec 23, 7:03AM CST
In accordance with Rule 2.10 of the Irish Takeover Rules, Covidien plc (NYSE: COV) (the "Company"
confirms that, as of the close of business on December 22, 2014, the Company's issued share capital, excluding treasury shares, consisted of 453,883,765 ordinary shares, par value US$0.20 per share (the "Ordinary Shares" . The International Securities Identification Number (ISIN) of the Ordinary Shares is IE00B68SQD29. COV: 103.35 (+0.57)
Watch for Covidien to Potentially Pullback After Gaining 1.13% Yesterday
Comtex SmarTrend(R) - Mon Dec 22, 4:00PM CST
Covidien (NYSE:COV) traded in a range yesterday that spanned from a low of $102.83 to a high of $104.06. Yesterday, the shares gained 1.1%, which took the trading range above the 3-day high of $103.89 on volume of 3.9 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
COV: 103.35 (+0.57)
After Yesterday's Rally of 1.13% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Mon Dec 22, 3:59PM CST
Covidien (NYSE:COV) traded in a range yesterday that spanned from a low of $102.83 to a high of $104.06. Yesterday, the shares gained 1.1%, which took the trading range above the 3-day high of $103.89 on volume of 3.9 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
COV: 103.35 (+0.57)
Covidien's board declares USD0.36 per ordinary share dividend
M2 - Mon Dec 22, 7:13AM CST
Covidien (NYSE:COV), a health care company, declared on Friday that its board of directors approved a dividend of USD0.36 per ordinary share of its stock.
COV: 103.35 (+0.57)
5 Health Care Stocks John Paulson Is Buying Ahead of 2015
at The Street - Mon Dec 22, 6:00AM CST
Here's a closer look at five stocks Paulson & Co. bought in the most recently reported quarter.
MNK: 97.84 (-0.29), HCA: 74.89 (-0.11), COV: 103.35 (+0.57), MYL: 56.97 (+0.39), ABBV: 66.21 (+1.86)
Covidien declares $0.36 dividend
Seeking Alpha - at Seeking Alpha - Fri Dec 19, 3:39PM CST
COV: 103.35 (+0.57)
Covidien Declares Quarterly Cash Dividend
Business Wire - Fri Dec 19, 3:30PM CST
Covidien plc (NYSE: COV) today announced that its Board of Directors has declared a quarterly cash dividend of $0.36 per ordinary share. The quarterly dividend is payable on Jan. 16, 2015, to shareholders of record on Jan. 2, 2015.
COV: 103.35 (+0.57)
Great Stocks: Mallinckrodt Rebounds, But Is It A Buy?
at Investor's Business Daily - Thu Dec 18, 5:09PM CST
Specialty drugmaker Mallinckrodt (MNK) has rebounded off its 10-week moving average for the third time since it broke out of a cup base in early September. But should investors buy the bounce? Mallinckrodt cleared an 83.30 cup-base buy point Sept. 3...
MNK: 97.84 (-0.29), COV: 103.35 (+0.57)
41.5% Return Seen to Date on SmarTrend Covidien Call (COV)
Comtex SmarTrend(R) - Thu Dec 18, 9:42AM CST
SmarTrend identified an Uptrend for Covidien (NYSE:COV) on May 12th, 2014 at $72.16. In approximately 7 months, Covidien has returned 41.55% as of today's recent price of $102.14.
COV: 103.35 (+0.57)
Masimo's Multigas Monitoring Module Gets 510(k), CE Mark - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Dec 17, 4:55PM CST
Masimo Corporation's (MASI) ISA OR+ multigas monitoring is a Masimo Open Connect (MOC-9) Module for the Root patient monitoring and connectivity platform.
MASI: 26.60 (+0.04), GMED: 24.37 (+0.44), COV: 103.35 (+0.57), EW: 130.75 (+1.17)
New Study Shows Addition of Stent Thrombectomy More Effective Than Traditional Pharmaceutical Treatment for Acute Ischemic Stroke Patients
Business Wire - Wed Dec 17, 9:01AM CST
In a landmark study evaluating the addition of stent thrombectomy clot removal to pharmaceutical treatment for patients suffering an acute ischemic stroke (AIS), stent thrombectomy provided a significant clinical benefit when compared to pharmaceutical treatment alone. Results from the Multi center Randomized Clinical trial of Endovascular treatment for Acute ischemic stroke in the Netherlands (MR CLEAN) have been published online and will appear in the January 1 issue of The New England Journal of Medicine ("NEJM"
. Findings were also presented at the World Stroke Congress, confirming the effectiveness of stent thrombectomy. COV: 103.35 (+0.57)
Covidien's Unique Capsule Endoscopy PillCam(R) SB Featured in New Smithsonian Exhibit 'Tools: Extending Our Reach'
Business Wire - Wed Dec 17, 6:57AM CST
PillCam(R) SB, Covidien's wireless capsule endoscope, is now featured in the exhibit, "Tools: Extending Our Reach" at New York's Cooper Hewitt Smithsonian Design Museum. PillCam SB is one of 175 installations highlighting how tools and innovations have extended the capabilities of the human body over the past two million years. The museum reopened on Dec. 12 after a three year renovation.
COV: 103.35 (+0.57)
Ostomy and Incontinence Products - 2014 Global Strategic Business Report: Incontinence Products Market to Thrive on Ageing Demographics
M2 - Wed Dec 17, 3:34AM CST
Research and Markets (http://www.researchandmarkets.com/research/v9dgkd/ostomy_and) has announced the addition of the "Ostomy and Incontinence Products - Global Strategic Business Report" report to their offering. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2013 through 2020. Also, a seven-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. This report analyzes the worldwide markets for Ostomy and Incontinence Products in US$ Thousands by the following Product Segments: - Incontinence Products (Disposable Adult Diapers, Disposable Adult Shields, Disposable Under Pads, Bags, Clamps, Cleaners, Deodorizers, & Urinals) - Ostomy Products (Ostomy Bags/Pouches, Deodorants, Irrigation Products, & Skin Barriers/Care Products). The report profiles 83 companies including many key and niche players such as: - Attends Healthcare Products, Inc. - B. Braun Melsungen AG - Cloplast A/S - ConvaTec, Inc. - Covidien Ltd. Key Topics Covered: I. Introduction, Methodology & Product Definitions II. Executive Summary 1. Global Market Overview 2. Key Growth Drivers & Restraints 3. Competition 4. Market Trends & Issues 5. Ostomy & Incontinence At A Glance 6. Treatment Options For Incontinence 7. Ostomy And Incontinence Products An Overview 8. Product Developments/Introductions 9. Recent Industry Activity 10. Focus On Select Global Players 11. Global Market Perspective III. Market 1. The United States 2. Canada 3. Japan 4. Europe 5. Asia-Pacific 6. Latin America 7. Rest Of World IV. Competitive Landscape Total Companies Profiled: 83 (including Divisions/Subsidiaries 97) - The United States (62) - Canada (2) - Japan (5) - Europe (22) - France (1) - Germany (3) - The United Kingdom (7) - Italy (1) - Rest of Europe (10) - Asia-Pacific (Excluding Japan) (6) For more information visit http://www.researchandmarkets.com/research/v9dgkd/ostomy_and
COV: 103.35 (+0.57)
Tax Inversions In The U.S.: We Gotta Get Out Of This Place
Cornell Business Review - Seeking Alpha - Sun Dec 14, 1:12PM CST
By Hunter Bosson Following a summer filled with foreign mergers, tax inversions have become the innovative and morally dubious business practice of 2014. As American firms shift their headquarters overseas, widespread claims that a continued...
MDT: 74.08 (+0.31), COV: 103.35 (+0.57), SHPG: 209.29 (+0.07), ABBV: 66.21 (+1.86), BKW: 35.50 (-1.16)
What Investors Can Learn From The Portfolios Of Fund Managers
Elite Wealth Management - at Seeking Alpha - Sun Dec 14, 4:47AM CST
MU: 34.91 (-0.06), ACT: 254.20 (-1.68), C: 54.54 (+0.12), COV: 103.35 (+0.57), CVI: 39.62 (unch), AET: 89.59 (+0.14), PCLN: 1,149.78 (+2.17), FDML: 15.99 (-0.40), TWX: 85.58 (-0.20), STAY: 19.60 (-0.31), HCA: 74.89 (-0.11), EBAY: 57.10 (-0.12), MRVL: 14.33 (+0.01), SUNE: 19.50 (+0.01), SHPG: 209.29 (+0.07), GLD: 112.77 (+0.03), GM: 33.43 (-0.13), IEP: 94.25 (+0.56), GOOGL: 536.93 (-1.84), TWC: 151.15 (+0.17), AIG: 56.28 (-0.16), AAPL: 112.01 (-0.53)
After Yesterday's Decline of 1.73%, Covidien Offers Investors Better Value
Comtex SmarTrend(R) - Wed Dec 10, 4:09PM CST
Covidien (NYSE:COV) traded in a range yesterday that spanned from a low of $101.49 to a high of $103.33. Yesterday, the shares fell 1.7%, which took the trading range below the 3-day low of $102.00 on volume of 3.0 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
COV: 103.35 (+0.57)
Health Care Stocks: A Year in Review and Predictions for 2015
at The Street - Wed Dec 10, 10:38AM CST
In 2014 drugmakers long on cash but short on growth bought quick access to markets that would have otherwise taken years to build. Can this continue?
ZMH: 114.11 (+0.64), ENDP: 72.10 (+0.34), BDX: 139.90 (+1.44), MDT: 74.08 (+0.31), COV: 103.35 (+0.57), ITMN: 73.89 (-0.02), BMY: 59.15 (-0.01), GSK: 42.85 (+0.11), JNJ: 104.59 (+0.31), CBST: 100.29 (-0.09), CFN: 59.18 (+0.04), SHPG: 209.29 (+0.07), AUXL: 34.40 (+0.18), ABBV: 66.21 (+1.86), IDIX: 24.50 (+0.05), SYK: 96.00 (-0.61), NVS: 93.91 (+0.66)
